Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
About this item
Full title
Author / Creator
Publisher
Cairo: Springer
Journal title
Language
English
Formats
Publication information
Publisher
Cairo: Springer
Subjects
More information
Scope and Contents
Contents
Myelofibrosis (MF) is characterized by splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, anemia, constitutional symptoms, and risk of secondary acute myeloid leukemia (sAML). The prognosis for sAML is very poor, with a median survival of less than 6 months, largely due to its resistance to treatment. The main cause of death in MF pa...
Alternative Titles
Full title
Inhibition of JAK2 and MDM2 to treat secondary acute myeloid leukemia evolving from myelofibrosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3145287302
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3145287302
Other Identifiers
ISSN
1110-8630
E-ISSN
2090-2441
DOI
10.1186/s43042-024-00616-0
